ClinicalTrials.gg

Program

recombinant human thrombopoietin

Also written as “Recombinant human thrombopoietin”, “rhTPO” and “Recombinant human thrombopoietin for injection (rhTPO)”.

Its studies are mostly in Thrombocytopenia · Liver Cirrhosis, led by 2 companies.

Furthest: phase 3, since Dec 31, 20214 company-led studies, 1 open or runningNext primary completion: Oct 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
3SBio30 open or runningphase 1since Dec 31, 2021Aug 15, 2018none ahead
MIBIO PTE.11 open or runningphase 3since Oct 28, 2026Oct 28, 2026Oct 31, 2028phase 3 · NCT07911800

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 15, 2018First study: early phase 1 study in Liver CirrhosisNew to 3SBio3SBio · NCT03673215 · 58 enrolled · China
  2. Dec 31, 2021Phase 1 study in Thrombocytopenia3SBio · NCT05193201 · 54 enrolled · China
  3. Oct 4, 2024Phase 1 study in Healthy Subjects3SBio · NCT06630494 · 22 enrolled · Australia
  4. Oct 28, 2026MIBIO PTE.’s first study: phase 3 study in ThrombocytopeniaNew to MIBIO PTE.MIBIO PTE. · NCT07911800 · 150 planned · Georgia

Ahead

  1. Oct 31, 2028Primary completion: phase 3 study in ThrombocytopeniaMIBIO PTE. · NCT07911800

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07911800Thrombocytopenia · Georgia3RecruitingMIBIO PTE.Oct 31, 2028150
NCT06630494Healthy Subjects · Australia1Completed3SBioNov 18, 202422
NCT05193201Thrombocytopenia · China1UNKNOWN3SBioOct 16, 202254
NCT03673215Liver Cirrhosis · ChinaEarly 1UNKNOWN3SBioOct 8, 202058

How it is read

Names in the registry

  • “Recombinant human thrombopoietin”, 4 entries
  • “rhTPO”, 1 entry
  • “Recombinant human thrombopoietin for injection (rhTPO)”, 1 entry
  • “recombinant human thrombopoietin injection”, 1 entry
  • “recombinant human thrombopoietin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.